Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Chromosomal Testing Can Determine Brain Tumor Therapy, Outcomes

04.07.2006
A trial involving two types of rare, malignant but treatable brain tumors shows that missing portions of two chromosomes can predict which patients will likely do better with therapy. The results, says senior author Walter J. Curran Jr., M.D., professor and chair of radiation oncology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, represents a paradigm shift in treating such tumors, known as gliomas.

Reporting last week in the Journal of Clinical Oncology, Dr. Curran and a team of American and Canadian researchers, in conjunction with the Philadelphia-based Radiation Therapy Oncology Group (RTOG), a federally-supported clinical trials organization, found that among 289 patients with either anaplastic oligodendroglioma or anaplastic oligoastrocytoma receiving either a combination of three chemotherapy drugs with radiation or radiation alone, those whose tumors had deletions in chromosome locations 1p and 19q tended to live nearly two and a half times longer than those patients without the missing chromosome portions. The “median survival time” of patients with the deletions was greater than seven years, meaning that one-half lived at least that long. For those with tumors lacking such deletions, one-half lived at least 2.8 years.

“Leukemias used to be the only cancers where chromosomal deletions were part of the treatment decision-making process,” says Dr. Curran, who is also clinical director of the Kimmel Cancer Center at Jefferson. “Now, testing for such deletions in tumors should become mandatory for at least these types of gliomas.”

In the study, 147 patients received the chemotherapy and radiation, while 142 were given only radiation. These rare, malignant tumors can be effectively treated, though seldom “cured” with surgery and radiation. One controversy, explains Dr. Curran, was whether or not adding chemotherapy early in the treatment will help individuals live longer. Most thought that chemotherapy would be beneficial.

However, the researchers found little difference in survival after three years between the two groups. While the group who received chemotherapy and radiation lived nearly a year longer without evidence of the cancer growing, nearly two-thirds of those patients experienced significant toxic side effects from the treatment.

Dr. Curran explains that there was some indirect evidence that showed that individuals with these types of tumors who had chromosomal deletions fared better. When the scientists compared the patients who had deletions and those who did not, they found stunning results.

“While finding unexpectedly that adding chemotherapy didn’t help survival, equally important was the fact that we confirmed in a multicenter trial that the 1p and/or 19q deletion was highly predictive and prognostic of patient outcome, whether the patient received radiation and chemotherapy or radiation alone,” Dr. Curran says. “Whether the patient had one or both deletions, the survival is much better.”

In the same journal issue, a European team showed nearly identical results in a similar trial. Both trials showed such deletions were predictive of survival, Dr. Curran says.

“These two studies together have shifted the way we think of anaplastic or grade three gliomas,” he says. “Up until now we’ve categorized them based on histologic appearance. We are now categorizing them according to chromosomal deletion status.”

“That’s actually more predictive than what they look like under the microscope,” Dr. Curran says. “Those who have no chromosomal deletions have outcomes not all that different than the grade four glioblastomas, a much more deadly brain tumor. Those with both deletions are a totally different group of patients.”

“Testing for chromosomal deletions should be a mandatory part now of the management of these patients based on these two trials.”

“There has been a shift in clinical trial design in the last year,” he says. “Now in patients with gliomas, we are going to apply this to future study design and probably treatment recommendations based on chromosomal deletions. I think more and more centers will begin to use such diagnostic genetics.”

Steve Benowitz | EurekAlert!
Further information:
http://www.jefferson.edu

More articles from Health and Medicine:

nachricht Usher syndrome: Gene therapy restores hearing and balance
25.09.2017 | Institut Pasteur

nachricht MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer
25.09.2017 | Case Western Reserve University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The fastest light-driven current source

Controlling electronic current is essential to modern electronics, as data and signals are transferred by streams of electrons which are controlled at high speed. Demands on transmission speeds are also increasing as technology develops. Scientists from the Chair of Laser Physics and the Chair of Applied Physics at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have succeeded in switching on a current with a desired direction in graphene using a single laser pulse within a femtosecond ¬¬ – a femtosecond corresponds to the millionth part of a billionth of a second. This is more than a thousand times faster compared to the most efficient transistors today.

Graphene is up to the job

Im Focus: LaserTAB: More efficient and precise contacts thanks to human-robot collaboration

At the productronica trade fair in Munich this November, the Fraunhofer Institute for Laser Technology ILT will be presenting Laser-Based Tape-Automated Bonding, LaserTAB for short. The experts from Aachen will be demonstrating how new battery cells and power electronics can be micro-welded more efficiently and precisely than ever before thanks to new optics and robot support.

Fraunhofer ILT from Aachen relies on a clever combination of robotics and a laser scanner with new optics as well as process monitoring, which it has developed...

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Fraunhofer ISE Pushes World Record for Multicrystalline Silicon Solar Cells to 22.3 Percent

25.09.2017 | Power and Electrical Engineering

Usher syndrome: Gene therapy restores hearing and balance

25.09.2017 | Health and Medicine

An international team of physicists a coherent amplification effect in laser excited dielectrics

25.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>